7 results about "Differentiation Inducer" patented technology

The invention provides an embryonic stem cell differentiation technology and application of the embryonic stem cell differentiation technology in screening of unknown risk alternative toxicity of a novel biological breeding product, and Cry1Ab protein is used as a test substance to evaluate the developmental toxicity of the Cry1Ab protein. The EBs are generated through hanging drop culture, and bone differentiation induction substances (beta-glycerophosphate, ascorbic acid and vitamin D3) are added to promote differentiation of the EBs. After bone cell induced differentiation is finished, the differentiation condition of bone cells is observed through alizarin red S dyeing and absorbance value detection, the cell growth condition is observed through cell total protein concentration and alkaline phosphatase activity detection, and then the influence of a test substance on the bone differentiation process is analyzed through the gene expression condition of osteogenic differentiation related markers (Runx2, SPARC and I-type collagen). The invention solves the problem of evaluating the unknown risk of a novel biological breeding product in vitro, creates an embryonic stem cell bone differentiation test technology, and uses the embryonic stem cell bone differentiation test technology as a screening method for the unknown risk alternative toxicity of the novel biological breeding product to be combined with an embryonic stem cell myocardial differentiation experiment for use. And the accuracy of predicating the developmental toxicity of the test substance is improved.

To provide a novel differentiation inducer to skeletal muscle Type I cells, which uses a component that was not previously known to induce differentiation to Type I fibers.SOLUTION: A differentiation inducer to skeletal muscle Type I cells includes R-spondin 3.SELECTED DRAWING: None

The application discloses a cerium nanoscale enzyme composite active material and application thereof in liver failure treatment, and belongs to the technical field of nanomaterials. The application combines miR122 and cerium dioxide nanoscale enzyme functions, develops a new stem cell differentiation inducer, i.e., a cerium nanoscale enzyme composite active material, and deeply studies the potential mechanism of catalytically active nanoscale enzyme material in regulating stem cell fate. After modification, the cerium dioxide nanoscale enzyme can be used for delivering miR122 into stem cells, so that miR122 is highly enriched in cells, thereby inducing liver differentiation. Meanwhile, the catalytic activity of the cerium dioxide nanoscale enzyme can regulate intracellular ROS homeostasis, protect mitochondria from ROS-induced damage, thereby maintaining mitochondrial function and meeting the energy demand in the differentiation process, which is crucial for the successful differentiation of stem cells. In order to solve the problem of impaired viability in hepatocyte transplantation, it is proposed to coat a layer of Ce 4+ -polyphenol skeleton on the surface of induced hepatocyte-like cells (iHLCs), further protecting the function and viability of hepatocytes after transplantation, and improving the in-vivo treatment effect.

The objective is to provide a previously unknown adipocyte differentiation inducer. [Solution] A fat cell differentiation inducer containing sesamolinol as an active ingredient.

A method and composition for treating cancer through induction of tumor cell differentiation is disclosed. Cancer cells are converted into terminally differentiated, non-proliferating cell types using specific differentiation-inducing agents, including thyroid hormone analogs such as T2 and RT3. The approach avoids the cytotoxic effects and side effects associated with conventional chemotherapy while potentially providing curative treatment. Pharmaceutical compositions include topical formulations for skin cancer treatment and various delivery systems for systemic administration. In vitro screening methods for identifying differentiation-inducing agents are also provided.

Provided is reproducible means that enables the production of an active nucleus pulposus cell phenotype from desired cells such as terminally differentiated cells or pluripotent or multipotent stem cells. Provided is a differentiation inducer containing an effective amount of a gene of at least two transcription factors selected from the group consisting of Brachyury (T), SRY-box6 (SOX6), and Forkhead Box Q1 (FOXQ1), or homologs thereof (nucleus pulposus cell master regulator transcription factor), or a product thereof.

To provide a method for producing retinal pigment epithelial cells.SOLUTION: A method of producing retinal pigment epithelium (RPE) cells, comprising the steps of: (a) culturing a cell population of undifferentiated human pluripotent stem cells on an adherent surface selected from the group consisting of laminin, fibronectin, vitronectin, collagen I and collagen IV in a medium comprising nicotinamide as a differentiation-inducing agent and lacking activin A under feeder cell-free conditions to obtain differentiated cells; (b) culturing the differentiated cells on the adherent surface in a medium comprising nicotinamide and one or more members of the TGF β superfamily selected from the group consisting of TGF β 1, TGF β 3, and activin A to obtain RPE cells, wherein at least 50% of the cells in the population of cells are Oct4 + TRA-1-60 +.SELECTED DRAWING: Figure 1